High-temperature-resistant MMLV reverse transcriptase mutant and application thereof
By introducing specific mutation sites into MMLV reverse transcriptase to form high-temperature mutants, the problem of insufficient thermal stability of existing MMLV reverse transcriptase at high temperatures is solved, and efficient RNA-to-cDNA reverse transcription is achieved, which improves detection performance .
Patent Information
- Application Number
- CN202411144906.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-20
AI Technical Summary
Existing MMLV reverse transcriptases exhibit insufficient thermal stability at higher temperatures, affecting the reverse transcription efficiency and yield of RNA to cDNA, resulting in performance bottlenecks in detection and analysis.
High temperature-resistant reverse transcriptase mutants were formed by introducing specific mutation sites (H126E, F199L, T246H, W388R, A404N and D422E) into the amino acid sequence of MMLV reverse transcriptase, and high enzymes were screened through machine learning and rational design. Live and thermally stable mutants, combined with the application of nucleic acid molecules and biological materials, produce highly efficient enzyme preparations and products.
It realizes efficient reverse transcription on complex RNA templates, improves the yield and quality of cDNA synthesis, enhances the enzyme activity at temperatures above 55°C, and improves the performance of RT-PCR and RT-qPCR detection.
Smart Images

Figure BDA0005001944980000221 
Figure BDA0005001944980000231 
Figure HDA0005001944990000011
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a high temperature resistant MMLV reverse transcriptase mutant and application thereof. Background Art
[0002] During the COVID-19 pandemic, reverse transcription and polymerase chain reaction (known as RT-PCR) is an excellent method for detecting SARS-CoV-2. The MMLV reverse transcriptase from Moloney murine leukemia virus is the most commonly used cDNA synthesizer in molecular biology, where the synthesized cDNA can be used as a substrate for downstream PCR and qPCR applications.
[0003] As an indispensable tool for RNA research or detection, MMLV reverse transcriptase has undergone many improvements to improve different properties, the most important of which is thermal stability, because thermal stability largely determines the performance of MMLV reverse transcriptase in practical applications. Higher reaction temperatures, generally above 55°C, will open the secondary structure of the complex RNA template, allowing the reverse transcriptase to read the sequence, so that cDNA can be synthesized smoothly and continuously. Therefore, reverse transcriptases that can withstand higher temperatures can achieve full-length cDNA synthesis with higher yields, thereby enabling RNA to be better reverse transcribed into cDNA. Therefore, there is an urgent need to study reverse transcriptases with better thermal stability and amplification efficiency. Summary of the invention
[0004] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a thermostable MMLV reverse transcriptase mutant.
[0005] The present invention also provides a nucleic acid molecule encoding the above-mentioned high temperature resistant MMLV reverse transcriptase mutant.
[0006] The present invention also provides biological materials related to the above nucleic acid molecules.
[0007] The present invention also provides an enzyme preparation.
[0008] The present invention also provides applications of the high temperature resistant MMLV reverse transcriptase mutant, nucleic acid molecule and biological material.
[0009] The invention also provides a product.
[0010] The present invention also provides a method for preparing the high temperature resistant MMLV reverse transcriptase mutant.
[0011] According to a first aspect of the present invention, a thermostable MMLV reverse transcriptase mutant is proposed, wherein an amino acid site mutation is performed on the basis of the amino acid sequence of the wild-type MMLV reverse transcriptase as shown in SEQ ID NO: 1, and the amino acid mutation site includes one or more of H126E, F199L, T246H, W388R, A404N and D422E.
[0012] In some embodiments of the present invention, the high temperature is represented by a temperature > 55°C.
[0013] In some embodiments of the present invention, the high temperature is 56, 57, 58, 59, 60, 61, 62, 63, 64, 65°C.
[0014] In some embodiments of the present invention, the thermostable MMLV reverse transcriptase mutant can also achieve a better reverse transcription effect than the wild type under the condition of ≤55°C.
[0015] In some embodiments of the present invention, the amino acid sequence of the thermostable MMLV reverse transcriptase mutant is shown in any one of SEQ ID NOs: 2-7.
[0016] According to a second aspect of the present invention, a nucleic acid molecule is provided, wherein the nucleic acid molecule encodes the above-mentioned thermostable MMLV reverse transcriptase mutant.
[0017] In some embodiments of the present invention, the nucleotide sequence of the nucleic acid molecule is:
[0018] (1) a nucleotide sequence as shown in any one of SEQ ID NOs: 9-14; or,
[0019] (2) A synonymous codon sequence of the thermostable MMLV reverse transcriptase mutant that is the same as the nucleotide sequence described in (1).
[0020] According to a third aspect of the present invention, a biological material related to the nucleic acid molecule is provided, wherein the biological material comprises at least one of a1) to a7):
[0021] a1) an expression cassette comprising the above nucleic acid molecule;
[0022] a2) a vector comprising the above nucleic acid molecule;
[0023] a3) a vector comprising the expression cassette described in a1);
[0024] a4) a transgenic cell line comprising the above nucleic acid molecule;
[0025] a5) a transgenic cell line comprising the expression cassette described in a1);
[0026] a6) a transgenic cell line comprising the vector described in a2);
[0027] a7) A transgenic cell line comprising the vector described in a3).
[0028] According to a fourth aspect of the present invention, an enzyme preparation is provided, comprising the above-mentioned thermostable MMLV reverse transcriptase mutant.
[0029] According to a fifth aspect of the present invention, an application of the above-mentioned thermostable MMLV reverse transcriptase mutant, nucleic acid molecule, biomaterial and enzyme preparation is proposed, and the application is an application in preparing a product.
[0030] In some embodiments of the present invention, the product comprises at least one of a reagent, a detection plate, a test kit, and a detection chip.
[0031] In some embodiments of the present invention, the reagent, detection plate, detection chip or kit has at least one of the functions b1) to b3):
[0032] b1) Detect RNA samples;
[0033] b2) reverse transcription of RNA to synthesize cDNA;
[0034] b3) preparing RT-PCR detection reagents or RT-qPCR detection reagents.
[0035] According to a sixth aspect of the present invention, a product is provided, wherein the product comprises the above-mentioned thermostable MMLV reverse transcriptase mutant.
[0036] In some embodiments of the present invention, the product comprises at least one of a reagent, a detection plate, a test kit, and a detection chip.
[0037] In some embodiments of the present invention, the reagent, detection plate, detection chip or kit has at least one of the functions b1) to b3):
[0038] b1) Detect RNA samples;
[0039] b2) reverse transcription of RNA to synthesize cDNA;
[0040] b3) preparing RT-PCR detection reagents or RT-qPCR detection reagents.
[0041] In some embodiments of the present invention, the kit is selected from a reverse transcription reaction kit, a RT-PCR amplification kit, a RT-qPCR kit, a cDNA library construction kit, a cDNA end rapid amplification kit and an RNA sequencing kit.
[0042] In some embodiments of the present invention, the reverse transcription reaction kit further comprises: at least one of a reverse transcription reaction buffer, dNTPs, an RNase inhibitor and a reverse transcription reaction primer.
[0043] In some embodiments of the present invention, the RT-PCR amplification kit further comprises: at least one of PCR water, RT-PCR amplification buffer, dNTPs, DNA polymerase and PCR amplification primers.
[0044] In some embodiments of the present invention, the RT-qPCR kit further comprises: at least one of PCR water, RT-qPCR amplification buffer, dNTPs, DNA polymerase, qPCR amplification primers and probes.
[0045] In some embodiments of the present invention, the cDNA library construction kit further comprises: a linker.
[0046] According to a seventh aspect of the present invention, a method for preparing the above-mentioned thermostable MMLV reverse transcriptase mutant is provided, and the preparation method comprises the following steps: obtaining it by expressing it through the above-mentioned transgenic cell line.
[0047] In some embodiments of the present invention, the method specifically comprises the following steps:
[0048] (1) transferring the recombinant vector containing the above-mentioned nucleic acid molecule into competent cells and culturing them, and picking single clone cells for screening;
[0049] (2) extracting the expression vector of the screened positive clone, transferring it into host cells, inoculating it into a culture medium for cultivation, and obtaining a seed solution;
[0050] (3) taking the obtained seed liquid and inoculating it into a culture medium for culturing to obtain a bacterial liquid;
[0051] (4) adding the inducer IPTG to the obtained bacterial solution to a final concentration of 0.8 to 1 mmol / L, inducing expression, and collecting the bacterial cells by centrifugation;
[0052] (5) adding lysis buffer to the obtained bacterial cells for resuspending, crushing the bacterial cells under high pressure, centrifuging to obtain the supernatant; and filtering with a 0.22-0.5 μm microporous filter membrane;
[0053] (6) subjecting the filtered liquid phase to nickel ion affinity chromatography, detecting the eluted solution by polyacrylamide electrophoresis, and collecting a sample containing the target protein;
[0054] (7) The sample containing the target protein in step (6) is subjected to cation exchange chromatography, and the elution solution is detected by polyacrylamide gel electrophoresis. The sample containing the target protein is collected and dialyzed into a preservation solution to obtain the thermostable MMLV reverse transcriptase mutant.
[0055] In some embodiments of the present invention, the culture medium is LB medium.
[0056] In some embodiments of the present invention, the culture medium in step (2) and step (3) both contain 80-120 μg / mL ampicillin.
[0057] In some embodiments of the present invention, the culture conditions in step (2) are 20-30° C. and 150-200 r / min shaking culture.
[0058] In some embodiments of the present invention, the culture conditions in step (3) are: 20-30°C, 150-200 r / min shaking culture until OD600 is 0.6-0.8.
[0059] In some embodiments of the present invention, the seed solution in step (3) is inoculated into LB medium at a volume ratio of 1:(80-120).
[0060] In some embodiments of the present invention, the induction conditions in step (4) are 20-30° C. and the induction time is 4-6 hours.
[0061] In some embodiments of the present invention, the centrifugation conditions in step (4) are: centrifugation at 4000-5000 rpm at 2-6°C for 15-25 min.
[0062] In some embodiments of the present invention, the amount of lysis buffer in step (5) is 8 to 10 mL per gram of bacterial cells.
[0063] In some embodiments of the present invention, the centrifugation condition in step (5) is 2-6°C and 10000-14000 rpm for 25-35 min.
[0064] In some embodiments of the present invention, the components of the lysis buffer in step (5) include: 45-55 mM Tris-HCl, 280-320 mM NaCl, and 0.1%-0.2% Triton X-100.
[0065] In some embodiments of the present invention, the components of the binding buffer used for the nickel ion affinity chromatography in step (6) contain: 45-55 mM Tris-HCl, 280-320 mM NaCl, 15-25 mM Imidazole, and 2%-6% Glycerol.
[0066] In some embodiments of the present invention, the components of the elution buffer used in nickel ion affinity chromatography contain: 45-55 mM Tris-HCl, 280-320 mM NaCl, 200-300 mM Imidazole, and 2%-6% Glycerol.
[0067] In some embodiments of the present invention, the components of the binding buffer used in the cation exchange chromatography contain: 15-25 mM Tris-HCl, 190-220 mM NaCl, 2%-6% (V / V) Glycerol, 0.5-2 mM DTT, 0.5-2 mM EDTA.
[0068] In some embodiments of the present invention, the components of the gradient elution buffer used in cation exchange chromatography contain: 15-25 mM Tris-HCl, 550-650 mM NaCl, 2%-6% (V / V) Glycerol, 0.5-2 mM DTT, 0.5-2 mM EDTA.
[0069] In some embodiments of the present invention, the components of the preservation solution include: 15-25 mM Tris-HCl, 550-650 mM NaCl, 0.5-2 mM DTT, 40-60% Glycerol, and 0.5-2 mM EDTA.
[0070] According to some embodiments of the present invention, at least the following beneficial effects are achieved: the high-temperature resistant MMLV reverse transcriptase mutant prepared by the present invention is prepared by using machine learning and rational design to obtain numerous mutation sites, and the mutation sites are combined and screened to obtain the high-temperature resistant MMLV reverse transcriptase mutant, which has the advantages of higher enzyme activity and higher thermal stability than the wild type, and can be used for reverse transcription on complex RNA templates. BRIEF DESCRIPTION OF THE DRAWINGS
[0071] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:
[0072] Figure 1 is an SDS-PAGE image of the purified mutant and wild type in Example 1 of the present invention, wherein M is a marker; 1 is a wild-type MMLV reverse transcriptase, 2 is an MMLV reverse transcriptase mutant Mut1, 3 is an MMLV reverse transcriptase mutant Mut2, 4 is an MMLV reverse transcriptase mutant Mut3, 5 is an MMLV reverse transcriptase mutant Mut4, 6 is an MMLV reverse transcriptase mutant Mut5, and 7 is an MMLV reverse transcriptase mutant Mut6;
[0073] Figure 2It is a statistical graph of the enzyme activity of the thermostable MMLV reverse transcriptase mutant and the wild-type MMLV reverse transcriptase in Example 2 of the present invention, wherein 1 is the wild-type MMLV reverse transcriptase, 2 is the MMLV reverse transcriptase mutant Mut1, 3 is the MMLV reverse transcriptase mutant Mut2, 4 is the MMLV reverse transcriptase mutant Mut3, 5 is the MMLV reverse transcriptase mutant Mut4, 6 is the MMLV reverse transcriptase mutant Mut5, and 7 is the MMLV reverse transcriptase mutant Mut6;
[0074] Figure 3 is a curve diagram of the Tm values of MMLV reverse transcriptase mutants and wild-type MMLV, wherein 1 is wild-type MMLV reverse transcriptase, 2 is MMLV reverse transcriptase mutant Mut1, 3 is MMLV reverse transcriptase mutant Mut2, 4 is MMLV reverse transcriptase mutant Mut3, 5 is MMLV reverse transcriptase mutant Mut4, 6 is MMLV reverse transcriptase mutant Mut5, and 7 is MMLV reverse transcriptase mutant Mut6;
[0075] Figure 4 The curve of the change of the △Ct value of the high temperature resistant MMLV reverse transcriptase mutants compared with the △Ct value of the MMLV reverse transcriptase wild type treated with high temperature and untreated, wherein 1 is the MMLV reverse transcriptase mutant Mut1, 2 is the MMLV reverse transcriptase mutant Mut2, 3 is the MMLV reverse transcriptase mutant Mut3, 4 is the MMLV reverse transcriptase mutant Mut4, 5 is the MMLV reverse transcriptase mutant Mut5, and 6 is the MMLV reverse transcriptase mutant Mut6. DETAILED DESCRIPTION
[0076] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0077] Example 1 Transformation, expression, purification and identification of thermostable MMLV reverse transcriptase mutants
[0078] 1. Design of thermostable MMLV reverse transcriptase mutants
[0079] According to artificial intelligence machine learning and rational design, many mutation sites of MMLV reverse transcriptase mutants were predicted, and the mutation sites were combined to screen and obtain high temperature resistant MMLV reverse transcriptase mutants Mut1, Mut2, Mut3, Mut4, Mut5, and Mut6. The mutant sequences were obtained based on the sites of the wild-type MMLV reverse transcriptase (amino acid sequence as shown in SEQ ID NO: 1).
[0080] Wild-type MMLV reverse transcriptase:
[0081] (SEQ ID NO: 1).
[0082] The amino acid sequences of the mutants Mut1, Mut2, Mut3, Mut4, Mut5, and Mut6 are shown in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively.
[0083] Amino acid sequence of Mut1:
[0084] MLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDI E PTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTL L DEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGP R RRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLI(SEQID NO:2).
[0085] Amino acid sequence of Mut2:
[0086] MLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTP
[0087] VSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLR
[0088] EVNKRVEDI E PTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRD
[0089] PEMGISGQLTWTRLPQGFKNSPTL L DEALHRDLADFRIQHPDLILLQYVDDLLLAATS
[0090] ELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETV
[0091] MGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQ
[0092] EIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGP R RRPVAYLSKKLDPVA
[0093] N GWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTH
[0094] YQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDA
[0095] DHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAE
[0096] GKKLNVYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLI(SEQ ID NO:3)。
[0097] Mut3 amino acid sequence:
[0098] MLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDI E PTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTL L DEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGP R RRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTK E AGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLI(SEQ ID NO:4).
[0099] Mut4 amino acid sequence:
[0100] MLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDI EPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTL L DEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQ H LGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGP R RRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLI(SEQ ID NO:5).
[0101] Amino acid sequence of Mut5:
[0102] MLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDI E PTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTL LDEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGP R RRPVAYLSKKLDPVA N GWPPCLRMVAAIAVLTK E AGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLI(SEQ ID NO:6).
[0103] Amino acid sequence of Mut6:
[0104] MLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDI E PTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTL L DEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQ HLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGP R RRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTK E AGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAK ALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLI(SEQID NO:7).
[0105] Among them, the underscore “—” indicates the mutation site.
[0106] 2. Synthesis of thermostable MMLV reverse transcriptase mutants
[0107] (1) Recombinant expression vectors (the original vector is PET-32a) containing nucleotide sequences encoding MMLV reverse transcriptase mutants (the sequences of mutants Mut1-6 are shown in SEQ ID NOs: 9-14, respectively) and nucleotide sequences encoding MMLV reverse transcriptase wild-type (shown in SEQ ID NO: 8) were synthesized by whole gene synthesis.
[0108] Nucleotide sequence encoding wild-type MMLV reverse transcriptase:
[0109]
[0110] Nucleotide sequence encoding the MMLV reverse transcriptase mutant Mut 1:
[0111] ATGCTGAACATCGAAGACGAACACCGCCTGCACGAAACCTCCAAAGAACCGGATGTCAGCCTGGGTAGCACCTGGCTGTCTGACTTTCCTCAGGCGTGGGCCGAAACCGGCGGTATGGGCCTGGCAGTTCGTCAGGCGCCGCTGATCATTCCGCTGAAGGCGACGTCTACCCCGGTTTCCATCAAACAGTACCCGATGTCCCAGGAAGCCCGCCTGGGCATCAAACCGCACATCCAGCGTCTGCTGGATCAGGGCATCCTGGTGCCGTGCCAAAGCCCATGGAATACTCCACTGCTGCCGGTGAAAAAACCGGGTACCAACGACTATCGTCCTGTCCAGGACCTGCGCGAAGTGAACAAACGTGTGGAAGACATT GAA CCGACCGTTCCGAACCCGTACAATCTGCTGTCCGGCCTGCCGCCGTCCCACCAATGGTATACGGTTCTGGATCTGAAAGACGCGTTTTTTTGTCTGCGTCTGCACCCGACCTCTCAGCCACTGTTCGCGTTTGAGTGGCGCGACCCGGAGATGGGCATCTCTGGTCAGCTGACCTGGACCCGTCTGCCGCAGGGCTTCAAAAACTCCCCGACCCTG CTGGATGAGGCTCTGCATCGCGATCTGGCGGACTTCCGTATCCAGCACCCGGACCTGATCCTGCTGCAGTATGTTGACGACCTGCTGCTGGCGGCAACTTCCGAACTGGATTGCCAACAAGGTACTCGCGCTCTGCTGCAGACCCTGGGCAACCTGGGCTATCGTGCCTCCGCCAAAAAAGCGCAGATTTGTCAGAAACAGGTGAAATACCTGGGCTACCTGCTGAAGGAAGGTCAGCGTTGGCTGACTGAAGCTCGTAAGGAAACCGTTATGGGTCAACCGACTCCGAAAACCCCGCGCCAGCTGCGTGAGTTCCTGGGTACTGCCGGTTTCTGCCGTCTGTGGATCCCAGGCTTCGCTGAAATGGCCGCGCCGCTGTATCCGCTGACTAAAACCGGTACTCTGTTCAACTGGGGTCCGGACCAACAGAAAGCTTATCAGGAAATCAAACAGGCTCTGCTGACTGCGCCGGCTCTGGGTCTGCCGGATCTGACTAAACCGTTCGAACTGTTCGTTGATGAAAAGCAGGGTTACGCAAAAGGCGTACTGACCCAGAAACTGGGTCCG CGTCGTCGTCCGGTCGCTTACCTGTCTAAGAAACTGGACCCAGTAGCAGCTGGTTGGCCGCCGTGCCTGCGTATGGTTGCAGCGATCGCTGTCCTGACCAAAGACGCGGGCAAACTGACCATGGGTCAGCCGCTGGTAATCCTGGCTCCGCATGCTGTGGAAGCTCTGGTAAAACAGCCTCCGGACCGTTGGCTGTCCAACGCACGCATGACCCATTATCAGGCGCTGCTGCTGGACACTGATCGCGTGCAATTCGGTCCTGTTGTTGCCCTGAACCCGGCTACCCTGCTGCCACTGCCGGAGGAGGGCCTGCAACACAACTGTCTGGACATCCTGGCGGAAGCTCACGGCACTCGTCCTGATCTGACTGACCAACCTCTGCCTGACGCGGATCACACCTGGTACACCGACGGTTCTAGCCTGCTGCAAGAAGGTCAACGCAAGGCGGGCGCAGCTGTTACCACTGAAACTGAAGTTATCTGGGCGAAAGCTCTGCCGGCTGGTACCTCTGCTCAGCGTGCTGAACTGATCGCTCTGACTCAGGCGCTGAAAATGGCAGAAGGCAAGAAACTGAACGTGTATACCGATTCTCGTTACGCTTTCGCCACCGCCCACATTCATGGTGAAATTTACCGTCGTCGTGGTCTGCTGACTAGCGAAGGCAAGGAGATTAAGAACAAGGATGAGATCCTGGCGCTGCTGAAAGCTCTGTTCCTGCCGAAACGCCTGTCCATCATCCACTGTCCAGGCCACCAGAAAGGTCACTCCGCCGAAGCACGTGGTAATCGCATGGCGGACCAGGCAGCTCGTAAAGCTGCAATCACTGAAACTCCGGATACCTCTACGCTGCTGATC(SEQ ID NO:9).
[0112] Nucleotide sequence encoding MMLV reverse transcriptase mutant Mut 2:
[0113] ATGCTGAACATCGAAGACGAACACCGCCTGCACGAAACCTCCAAAGAACCGGATGTCAGCCTGGGTAGCACCTGGCTGTCTGACTTTCCTCAGGCGTGGGCCGAAACCGGCGGTATGGGCCTGGCAGTTCGTCAGGCGCCGCTGATCATTCCGCTGAAGGCGACGTCTACCCCGGTTTCCATCAAACAGTACCCGATGTCCCAGGAAGCCCGCCTGGGCATCAAACCGCACATCCAGCGTCTGCTGGATCAGGGCATCCTGGTGCCGTGCCAAAGCCCATGGAATACTCCACTGCTGCCGGTGAAAAAACCGGGTACCAACGACTATCGTCCTGTCCAGGACCTGCGCGAAGTGAACAAACGTGTGGAAGACATT GAA CCGACCGTTCCGAACCCGTACAATCTGCTGTCCGGCCTGCCGCCGTCCCACCAATGGTATACGGTTCTGGATCTGAAAGACGCGTTTTTTTGTCTGCGTCTGCACCCGACCTCTCAGCCACTGTTCGCGTTTGAGTGGCGCGACCCGGAGATGGGCATCTCTGGTCAGCTGACCTGGACCCGTCTGCCGCAGGGCTTCAAAAACTCCCCGACCCTG CTGGATGAGGCTCTGCATCGCGATCTGGCGGACTTCCGTATCCAGCACCCGGACCTGATCCTGCTGCAGTATGTTGACGACCTGCTGCTGGCGGCAACTTCCGAACTGGATTGCCAACAAGGTACTCGCGCTCTGCTGCAGACCCTGGGCAACCTGGGCTATCGTGCCTCCGCCAAAAAAGCGCAGATTTGTCAGAAACAGGTGAAATACCTGGGCTACCTGCTGAAGGAAGGTCAGCGTTGGCTGACTGAAGCTCGTAAGGAAACCGTTATGGGTCAACCGACTCCGAAAACCCCGCGCCAGCTGCGTGAGTTCCTGGGTACTGCCGGTTTCTGCCGTCTGTGGATCCCAGGCTTCGCTGAAATGGCCGCGCCGCTGTATCCGCTGACTAAAACCGGTACTCTGTTCAACTGGGGTCCGGACCAACAGAAAGCTTATCAGGAAATCAAACAGGCTCTGCTGACTGCGCCGGCTCTGGGTCTGCCGGATCTGACTAAACCGTTCGAACTGTTCGTTGATGAAAAGCAGGGTTACGCAAAAGGCGTACTGACCCAGAAACTGGGTCCG CGT CGTCGTCCGGTCGCTTACCTGTCTAAGAAACTGGACCCAGTAGCA AACGGTTGGCCGCCGTGCCTGCGTATGGTTGCAGCGATCGCTGTCCTGACCAAAGACGCGGGCAAACTGACCATGGGTCAGCCGCTGGTAATCCTGGCTCCGCATGCTGTGGAAGCTCTGGTAAAACAGCCTCCGGACCGTTGGCTGTCCAACGCACGCATGACCCATTATCAGGCGCTGCTGCTGGACACTGATCGCGTGCAATTCGGTCCTGTTGTTGCCCTGAACCCGGCTACCCTGCTGCCACTGCCGGAGGAGGGCCTGCAACACAACTGTCTGGACATCCTGGCGGAAGCTCACGGCACTCGTCCTGATCTGACTGACCAACCTCTGCCTGACGCGGATCACACCTGGTACACCGACGGTTCTAGCCTGCTGCAAGAAGGTCAACGCAAGGCGGGCGCAGCTGTTACCACTGAAACTGAAGTTATCTGGGCGAAAGCTCTGCCGGCTGGTACCTCTGCTCAGCGTGCTGAACTGATCGCTCTGACTCAGGCGCTGAAAATGGCAGAAGGCAAGAAACTGAACGTGTATACCGATTCTCGTTACGCTTTCGCCACCGCCCACATTCATGGTGAAATTTACCGTCGTCGTGGTCTGCTGACTAGCGAAGGCAAGGAGATTAAGAACAAGGATGAGATCCTGGCGCTGCTGAAAGCTCTGTTCCTGCCGAAACGCCTGTCCATCATCCACTGTCCAGGCCACCAGAAAGGTCACTCCGCCGAAGCACGTGGTAATCGCATGGCGGACCAGGCAGCTCGTAAAGCTGCAATCACTGAAACTCCGGATACCTCTACGCTGCTGATC(SEQ ID NO:10).
[0114] Nucleotide sequence encoding MMLV reverse transcriptase mutant Mut 3:
[0115] ATGCTGAACATCGAAGACGAACACCGCCTGCACGAAACCTCCAAAGAACCGGATGTCAGCCTGGGTAGCACCTGGCTGTCTGACTTTCCTCAGGCGTGGGCCGAAACCGGCGGTATGGGCCTGGCAGTTCGTCAGGCGCCGCTGATCATTCCGCTGAAGGCGACGTCTACCCCGGTTTCCATCAAACAGTACCCGATGTCCCAGGAAGCCCGCCTGGGCATCAAACCGCACATCCAGCGTCTGCTGGATCAGGGCATCCTGGTGCCGTGCCAAAGCCCATGGAATACTCCACTGCTGCCGGTGAAAAAACCGGGTACCAACGACTATCGTCCTGTCCAGGACCTGCGCGAAGTGAACAAACGTGTGGAAGACATT GAA CCGACCGTTCCGAACCCGTACAATCTGCTGTCCGGCCTGCCGCCGTCCCACCAATGGTATACGGTTCTGGATCTGAAAGACGCGTTTTTTTGTCTGCGTCTGCACCCGACCTCTCAGCCACTGTTCGCGTTTGAGTGGCGCGACCCGGAGATGGGCATCTCTGGTCAGCTGACCTGGACCCGTCTGCCGCAGGGCTTCAAAAACTCCCCGACCCTG CTGGATGAGGCTCTGCATCGCGATCTGGCGGACTTCCGTATCCAGCACCCGGACCTGATCCTGCTGCAGTATGTTGACGACCTGCTGCTGGCGGCAACTTCCGAACTGGATTGCCAACAAGGTACTCGCGCTCTGCTGCAGACCCTGGGCAACCTGGGCTATCGTGCCTCCGCCAAAAAAGCGCAGATTTGTCAGAAACAGGTGAAATACCTGGGCTACCTGCTGAAGGAAGGTCAGCGTTGGCTGACTGAAGCTCGTAAGGAAACCGTTATGGGTCAACCGACTCCGAAAACCCCGCGCCAGCTGCGTGAGTTCCTGGGTACTGCCGGTTTCTGCCGTCTGTGGATCCCAGGCTTCGCTGAAATGGCCGCGCCGCTGTATCCGCTGACTAAAACCGGTACTCTGTTCAACTGGGGTCCGGACCAACAGAAAGCTTATCAGGAAATCAAACAGGCTCTGCTGACTGCGCCGGCTCTGGGTCTGCCGGATCTGACTAAACCGTTCGAACTGTTCGTTGATGAAAAGCAGGGTTACGCAAAAGGCGTACTGACCCAGAAACTGGGTCCG CGT CGTCGTCCGGTCGCTTACCTGTCTAAGAAACTGGACCCAGTAGCAGCTGGTTGGCCGCCGTGCCTGCGTATGGTTGCAGCGATCGCTGTCCTGACCAAA GAAGCGGGCAAACTGACCATGGGTCAGCCGCTGGTAATCCTGGCTCCGCATGCTGTGGAAGCTCTGGTAAAACAGCCTCCGGACCGTTGGCTGTCCAACGCACGCATGACCCATTATCAGGCGCTGCTGCTGGACACTGATCGCGTGCAATTCGGTCCTGTTGTTGCCCTGAACCCGGCTACCCTGCTGCCACTGCCGGAGGAGGGCCTGCAACACAACTGTCTGGACATCCTGGCGGAAGCTCACGGCACTCGTCCTGATCTGACTGACCAACCTCTGCCTGACGCGGATCACACCTGGTACACCGACGGTTCTAGCCTGCTGCAAGAAGGTCAACGCAAGGCGGGCGCAGCTGTTACCACTGAAACTGAAGTTATCTGGGCGAAAGCTCTGCCGGCTGGTACCTCTGCTCAGCGTGCTGAACTGATCGCTCTGACTCAGGCGCTGAAAATGGCAGAAGGCAAGAAACTGAACGTGTATACCGATTCTCGTTACGCTTTCGCCACCGCCCACATTCATGGTGAAATTTACCGTCGTCGTGGTCTGCTGACTAGCGAAGGCAAGGAGATTAAGAACAAGGATGAGATCCTGGCGCTGCTGAAAGCTCTGTTCCTGCCGAAACGCCTGTCCATCATCCACTGTCCAGGCCACCAGAAAGGTCACTCCGCCGAAGCACGTGGTAATCGCATGGCGGACCAGGCAGCTCGTAAAGCTGCAATCACTGAAACTCCGGATACCTCTACGCTGCTGATC(SEQ ID NO:11).
[0116] Nucleotide sequence encoding MMLV reverse transcriptase mutant Mut 4:
[0117] ATGCTGAACATCGAAGACGAACACCGCCTGCACGAAACCTCCAAAGAACCGGATGTCAGCCTGGGTAGCACCTGGCTGTCTGACTTTCCTCAGGCGTGGGCCGAAACCGGCGGTATGGGCCTGGCAGTTCGTCAGGCGCCGCTGATCATTCCGCTGAAGGCGACGTCTACCCCGGTTTCCATCAAACAGTACCCGATGTCCCAGGAAGCCCGCCTGGGCATCAAACCGCACATCCAGCGTCTGCTGGATCAGGGCATCCTGGTGCCGTGCCAAAGCCCATGGAATACTCCACTGCTGCCGGTGAAAAAACCGGGTACCAACGACTATCGTCCTGTCCAGGACCTGCGCGAAGTGAACAAACGTGTGGAAGACATT GAA CCGACCGTTCCGAACCCGTACAATCTGCTGTCCGGCCTGCCGCCGTCCCACCAATGGTATACGGTTCTGGATCTGAAAGACGCGTTTTTTTGTCTGCGTCTGCACCCGACCTCTCAGCCACTGTTCGCGTTTGAGTGGCGCGACCCGGAGATGGGCATCTCTGGTCAGCTGACCTGGACCCGTCTGCCGCAGGGCTTCAAAAACTCCCCGACCCTG CTG GATGAGGCTCTGCATCGCGATCTGGCGGACTTCCGTATCCAGCACCCGGACCTGATCCTGCTGCAGTATGTTGACGACCTGCTGCTGGCGGCAACTTCCGAACTGGATTGCCAACAAGGTACTCGCGCTCTGCTGCAG CATCTGGGCAACCTGGGCTATCGTGCCTCCGCCAAAAAAGCGCAGATTTGTCAGAAACAGGTGAAATACCTGGGCTACCTGCTGAAGGAAGGTCAGCGTTGGCTGACTGAAGCTCGTAAGGAAACCGTTATGGGTCAACCGACTCCGAAAACCCCGCGCCAGCTGCGTGAGTTCCTGGGTACTGCCGGTTTCTGCCGTCTGTGGATCCCAGGCTTCGCTGAAATGGCCGCGCCGCTGTATCCGCTGACTAAAACCGGTACTCTGTTCAACTGGGGTCCGGACCAACAGAAAGCTTATCAGGAAATCAAACAGGCTCTGCTGACTGCGCCGGCTCTGGGTCTGCCGGATCTGACTAAACCGTTCGAACTGTTCGTTGATGAAAAGCAGGGTTACGCAAAAGGCGTACTGACCCAGAAACTGGGTCCG CGTCGTCGTCCGGTCGCTTACCTGTCTAAGAAACTGGACCCAGTAGCAGCTGGTTGGCCGCCGTGCCTGCGTATGGTTGCAGCGATCGCTGTCCTGACCAAAGACGCGGGCAAACTGACCATGGGTCAGCCGCTGGTAATCCTGGCTCCGCATGCTGTGGAAGCTCTGGTAAAACAGCCTCCGGACCGTTGGCTGTCCAACGCACGCATGACCCATTATCAGGCGCTGCTGCTGGACACTGATCGCGTGCAATTCGGTCCTGTTGTTGCCCTGAACCCGGCTACCCTGCTGCCACTGCCGGAGGAGGGCCTGCAACACAACTGTCTGGACATCCTGGCGGAAGCTCACGGCACTCGTCCTGATCTGACTGACCAACCTCTGCCTGACGCGGATCACACCTGGTACACCGACGGTTCTAGCCTGCTGCAAGAAGGTCAACGCAAGGCGGGCGCAGCTGTTACCACTGAAACTGAAGTTATCTGGGCGAAAGCTCTGCCGGCTGGTACCTCTGCTCAGCGTGCTGAACTGATCGCTCTGACTCAGGCGCTGAAAATGGCAGAAGGCAAGAAACTGAACGTGTATACCGATTCTCGTTACGCTTTCGCCACCGCCCACATTCATGGTGAAATTTACCGTCGTCGTGGTCTGCTGACTAGCGAAGGCAAGGAGATTAAGAACAAGGATGAGATCCTGGCGCTGCTGAAAGCTCTGTTCCTGCCGAAACGCCTGTCCATCATCCACTGTCCAGGCCACCAGAAAGGTCACTCCGCCGAAGCACGTGGTAATCGCATGGCGGACCAGGCAGCTCGTAAAGCTGCAATCACTGAAACTCCGGATACCTCTACGCTGCTGATC(SEQ ID NO:12).
[0118] Nucleotide sequence encoding MMLV reverse transcriptase mutant Mut 5:
[0119] ATGCTGAACATCGAAGACGAACACCGCCTGCACGAAACCTCCAAAGAACCGGATGTCAGCCTGGGTAGCACCTGGCTGTCTGACTTTCCTCAGGCGTGGGCCGAAACCGGCGGTATGGGCCTGGCAGTTCGTCAGGCGCCGCTGATCATTCCGCTGAAGGCGACGTCTACCCCGGTTTCCATCAAACAGTACCCGATGTCCCAGGAAGCCCGCCTGGGCATCAAACCGCACATCCAGCGTCTGCTGGATCAGGGCATCCTGGTGCCGTGCCAAAGCCCATGGAATACTCCACTGCTGCCGGTGAAAAAACCGGGTACCAACGACTATCGTCCTGTCCAGGACCTGCGCGAAGTGAACAAACGTGTGGAAGACATT GAA CCGACCGTTCCGAACCCGTACAATCTGCTGTCCGGCCTGCCGCCGTCCCACCAATGGTATACGGTTCTGGATCTGAAAGACGCGTTTTTTTGTCTGCGTCTGCACCCGACCTCTCAGCCACTGTTCGCGTTTGAGTGGCGCGACCCGGAGATGGGCATCTCTGGTCAGCTGACCTGGACCCGTCTGCCGCAGGGCTTCAAAAACTCCCCGACCCTG CTGGATGAGGCTCTGCATCGCGATCTGGCGGACTTCCGTATCCAGCACCCGGACCTGATCCTGCTGCAGTATGTTGACGACCTGCTGCTGGCGGCAACTTCCGAACTGGATTGCCAACAAGGTACTCGCGCTCTGCTGCAGACCCTGGGCAACCTGGGCTATCGTGCCTCCGCCAAAAAAGCGCAGATTTGTCAGAAACAGGTGAAATACCTGGGCTACCTGCTGAAGGAAGGTCAGCGTTGGCTGACTGAAGCTCGTAAGGAAACCGTTATGGGTCAACCGACTCCGAAAACCCCGCGCCAGCTGCGTGAGTTCCTGGGTACTGCCGGTTTCTGCCGTCTGTGGATCCCAGGCTTCGCTGAAATGGCCGCGCCGCTGTATCCGCTGACTAAAACCGGTACTCTGTTCAACTGGGGTCCGGACCAACAGAAAGCTTATCAGGAAATCAAACAGGCTCTGCTGACTGCGCCGGCTCTGGGTCTGCCGGATCTGACTAAACCGTTCGAACTGTTCGTTGATGAAAAGCAGGGTTACGCAAAAGGCGTACTGACCCAGAAACTGGGTCCG CGT CGTCGTCCGGTCGCTTACCTGTCTAAGAAACTGGACCCAGTAGCA AAC GGTTGGCCGCCGTGCCTGCGTATGGTTGCAGCGATCGCTGTCCTGACCAAA GAAGCGGGCAAACTGACCATGGGTCAGCCGCTGGTAATCCTGGCTCCGCATGCTGTGGAAGCTCTGGTAAAACAGCCTCCGGACCGTTGGCTGTCCAACGCACGCATGACCCATTATCAGGCGCTGCTGCTGGACACTGATCGCGTGCAATTCGGTCCTGTTGTTGCCCTGAACCCGGCTACCCTGCTGCCACTGCCGGAGGAGGGCCTGCAACACAACTGTCTGGACATCCTGGCGGAAGCTCACGGCACTCGTCCTGATCTGACTGACCAACCTCTGCCTGACGCGGATCACACCTGGTACACCGACGGTTCTAGCCTGCTGCAAGAAGGTCAACGCAAGGCGGGCGCAGCTGTTACCACTGAAACTGAAGTTATCTGGGCGAAAGCTCTGCCGGCTGGTACCTCTGCTCAGCGTGCTGAACTGATCGCTCTGACTCAGGCGCTGAAAATGGCAGAAGGCAAGAAACTGAACGTGTATACCGATTCTCGTTACGCTTTCGCCACCGCCCACATTCATGGTGAAATTTACCGTCGTCGTGGTCTGCTGACTAGCGAAGGCAAGGAGATTAAGAACAAGGATGAGATCCTGGCGCTGCTGAAAGCTCTGTTCCTGCCGAAACGCCTGTCCATCATCCACTGTCCAGGCCACCAGAAAGGTCACTCCGCCGAAGCACGTGGTAATCGCATGGCGGACCAGGCAGCTCGTAAAGCTGCAATCACTGAAACTCCGGATACCTCTACGCTGCTGATC(SEQ ID NO:13).
[0120] Nucleotide sequence encoding the MMLV reverse transcriptase mutant Mut 6:
[0121] ATGCTGAACATCGAAGACGAACACCGCCTGCACGAAACCTCCAAAGAACCGGATGTCAGCCTGGGTAGCACCTGGCTGTCTGACTTTCCTCAGGCGTGGGCCGAAACCGGCGGTATGGGCCTGGCAGTTCGTCAGGCGCCGCTGATCATTCCGCTGAAGGCGACGTCTACCCCGGTTTCCATCAAACAGTACCCGATGTCCCAGGAAGCCCGCCTGGGCATCAAACCGCACATCCAGCGTCTGCTGGATCAGGGCATCCTGGTGCCGTGCCAAAGCCCATGGAATACTCCACTGCTGCCGGTGAAAAAACCGGGTACCAACGACTATCGTCCTGTCCAGGACCTGCGCGAAGTGAACAAACGTGTGGAAGACATT GAA CCGACCGTTCCGAACCCGTACAATCTGCTGTCCGGCCTGCCGCCGTCCCACCAATGGTATACGGTTCTGGATCTGAAAGACGCGTTTTTTTGTCTGCGTCTGCACCCGACCTCTCAGCCACTGTTCGCGTTTGAGTGGCGCGACCCGGAGATGGGCATCTCTGGTCAGCTGACCTGGACCCGTCTGCCGCAGGGCTTCAAAAACTCCCCGACCCTG CTG GATGAGGCTCTGCATCGCGATCTGGCGGACTTCCGTATCCAGCACCCGGACCTGATCCTGCTGCAGTATGTTGACGACCTGCTGCTGGCGGCAACTTCCGAACTGGATTGCCAACAAGGTACTCGCGCTCTGCTGCAG CACCTGGGCAACCTGGGCTATCGTGCCTCCGCCAAAAAAGCGCAGATTTGTCAGAAACAGGTGAAATACCTGGGCTACCTGCTGAAGGAAGGTCAGCGTTGGCTGACTGAAGCTCGTAAGGAAACCGTTATGGGTCAACCGACTCCGAAAACCCCGCGCCAGCTGCGTGAGTTCCTGGGTACTGCCGGTTTCTGCCGTCTGTGGATCCCAGGCTTCGCTGAAATGGCCGCGCCGCTGTATCCGCTGACTAAAACCGGTACTCTGTTCAACTGGGGTCCGGACCAACAGAAAGCTTATCAGGAAATCAAACAGGCTCTGCTGACTGCGCCGGCTCTGGGTCTGCCGGATCTGACTAAACCGTTCGAACTGTTCGTTGATGAAAAGCAGGGTTACGCAAAAGGCGTACTGACCCAGAAACTGGGTCCG CGT CGTCGTCCGGTCGCTTACCTGTCTAAGAAACTGGACCCAGTAGCAGCTGGTTGGCCGCCGTGCCTGCGTATGGTTGCAGCGATCGCTGTCCTGACCAAA GAAGCGGGCAAACTGACCATGGGTCAGCCGCTGGTAATCCTGGCTCCGCATGCTGTGGAAGCTCTGGTAAAACAGCCTCCGGACCGTTGGCTGTCCAACGCACGCATGACCCATTATCAGGCGCTGCTGCTGGACACTGATCGCGTGCAATTCGGTCCTGTTGTTGCCCTGAACCCGGCTACCCTGCTGCCACTGCCGGAGGAGGGCCTGCAACACAACTGTCTGGACATCCTGGCGGAAGCTCACGGCACTCGTCCTGATCTGACTGACCAACCTCTGCCTGACGCGGATCACACCTGGTACACCGACGGTTCTAGCCTGCTGCAAGAAGGTCAACGCAAGGCGGGCGCAGCTGTTACCACTGAAACTGAAGTTATCTGGGCGAAAGCTCTGCCGGCTGGTACCTCTGCTCAGCGTGCTGAACTGATCGCTCTGACTCAGGCGCTGAAAATGGCAGAAGGCAAGAAACTGAACGTGTATACCGATTCTCGTTACGCTTTCGCCACCGCCCACATTCATGGTGAAATTTACCGTCGTCGTGGTCTGCTGACTAGCGAAGGCAAGGAGATTAAGAACAAGGATGAGATCCTGGCGCTGCTGAAAGCTCTGTTCCTGCCGAAACGCCTGTCCATCATCCACTGTCCAGGCCACCAGAAAGGTCACTCCGCCGAAGCACGTGGTAATCGCATGGCGGACCAGGCAGCTCGTAAAGCTGCAATCACTGAAACTCCGGATACCTCTACGCTGCTGATC(SEQ ID NO:14).
[0122] Among them, the underlined "-" represents the nucleotide sequence of the mutation site.
[0123] (2) The obtained recombinant expression vector was transformed into the host cell E. coli BL21 (DE3). After cultivation, a single colony was picked and inoculated into LB (containing 100 μg / mL ampicillin) liquid culture medium and cultured until OD600 was 0.6-0.8. IPTG was added to a final concentration of 1.0 mmol / L and induced at 25°C for 5 h. The cells were collected by centrifugation at 4°C and 4200 rpm, lysis buffer was added and ultrasonically disrupted, and the expression of the target protein was detected by SDS-PAGE electrophoresis. The detection results were as follows: Figure 2 As shown, the results showed that the target protein could be expressed efficiently, and the sequence was verified to be correct.
[0124] (3) The recombinant bacteria capable of expressing the MMLV reverse transcriptase mutant obtained in step (2) were inoculated into 100 mL of LB medium containing 100 μg / mL of ampicillin, and placed in a shaking incubator at 25° C. for overnight shaking culture to obtain a seed solution.
[0125] (4) The seed solution obtained from the overnight culture was inoculated into 2 L of LB medium containing 100 μg / mL ampicillin at a volume ratio of 1:100, and cultured in a shaker at 25°C until the OD600 was 0.6-0.8; IPTG was added to a final concentration of 1.0 mmol / L, and the shaking induction was continued at 25°C for 5 h; the induced bacteria were collected by centrifugation and weighed, the wet weight of the bacteria was recorded, and stored at -20°C.
[0126] (5) Take the cells frozen at -20°C after induction of expression, add 10 mL of lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 0.15% Triton X-100, pH 7.8) per gram of cells to resuspend the cells according to the recorded wet weight of the cells, and lyse the cells with a high-pressure crusher. Centrifuge the lysed cells at 12,000 rpm for 30 min at 4°C. Centrifuge the supernatant at 12,000 rpm for 30 min at 4°C, filter with a 0.22 μm microporous filter membrane, take the supernatant to a 200 mL sterile beaker, and purify using a Ni affinity chromatography column.
[0127] (6) Ni affinity chromatography column purification
[0128] Experimental reagents: The binding buffer was buffer A: 50 mM Tris-HCl, 300 mM NaCl, 20 mM Imidazole, 5% Glycerol, pH 7.8; the elution buffer was buffer B: 50 mM Tris-HCl, 300 mM NaCl, 250 mM Imidazole, 5% Glycerol, pH 7.8.
[0129] Experimental method: The supernatant filtered through a 0.22 μm microporous membrane was loaded onto a chromatography column equilibrated with buffer A. After loading, the column was first rinsed with equilibrated solution A, and then gradient eluted with buffer B at 0%-100%, and the eluted components were tested by SDS-PAGE protein electrophoresis. The eluate was collected according to the test results and dialyzed into buffer C for later use.
[0130] (7) Cation exchange chromatography purification
[0131] Experimental reagents: The binding buffer is buffer C: 20mM Tris-HCl, 200mM NaCl, 5% (V / V) Glycerol, 1mM DTT, 1mM EDTA, pH7.8; the elution buffer is buffer D: 20mM Tris-HCl, 600mM NaCl, 5% (V / V) Glycerol, 1mM DTT, 1mM EDTA, pH7.8; the preservation solution: 20mM Tris-HCl, 600mM NaCl, 1mM DTT, 50% Glycerol, 1mM EDTA, pH7.8.
[0132] Experimental method: The dialysate sample obtained by purification of the Ni affinity chromatography column was loaded onto the chromatography column equilibrated with buffer C. After loading, the column was first rinsed with equilibrated solution C, and then gradient eluted with buffer D at 0%-100%, and the eluted components were tested by SDS-PAGE protein electrophoresis. The eluate was collected according to the test results, dialyzed with a dialysis bag with a molecular weight of 10KDa, and then stored in the storage solution for standby use, and the concentration of the purified mutant was determined by the Coomassie Brilliant Blue method.
[0133] Example 2 Detection of enzyme activity of thermostable MMLV reverse transcriptase mutant and wild type
[0134] In this example, the enzyme activity of the thermostable MMLV reverse transcriptase mutant obtained in Example 1 was detected. The specific method is as follows:
[0135] The thermostable MMLV reverse transcriptase mutants Mut1, Mut2, Mut3, Mut4, Mut5, Mut6 and wild-type WT purified in Example 1 were tested for reverse transcriptase activity according to the following method, and the specific steps included: the MMLV reverse transcriptase mutants prepared in Example 1 were used as the test samples of the experimental group, and the commercial wild-type MMLV reverse transcriptase (purchased from Hunan Aikerui Bioengineering Co., Ltd.) was used as the test sample of the control group, and a 5-fold gradient dilution was performed, and then 0.4 μg of MS2 RNA was used as a template for reverse transcription and quantitative qPCR. After the quantitative qPCR was completed, standard curves of the Ct and the logarithm of the enzyme activity concentration of the control substance and the test sample were prepared respectively, and the logarithm of the enzyme activity of the test sample was calculated. After solving the logarithm, the enzyme activity under different dilution multiples was calculated, and the average value was taken to obtain the reverse transcriptase activity. The specific operations of the reverse transcription reaction and the quantitative qPCR reaction are as follows:
[0136] Test 1: 5'-TTCAGCGAACTTCTTGTAA-3' (SEQ ID NO: 15);
[0137] Test 2: 5'-CATCCGTAGCCTTATTGG-3' (SEQ ID NO: 16).
[0138] (1) Using 0.4 μg of MS2 RNA as a template, reverse transcription was performed using a gradient diluted MMLV enzyme to obtain cDNA. The specific reverse transcription reaction system is as follows:
[0139] 20μL reverse transcription system: final concentration of 1×RTase Reaction Buffer Mix II, final concentration of 0.1μmo1 / L Test1, final concentration of 1U / μL RNase Inhibitor, 0.4μg MS2 RNA, 5μL diluted MMLV enzyme, add water to make up to 20μL.
[0140] The reverse transcription reaction program is 37℃, 30sec; 85℃, 5sec; 4℃, hold. Put it into the PCR instrument for reverse transcription reaction. After the reaction is completed, it can be placed at -20℃ for use.
[0141] (2) Quantitative qPCR reaction: The cDNA synthesized by reverse transcription in (1) was used as a template for qPCR reaction (N=2).
[0142] 25μL qPCR reaction system: final concentration is 1×SYBR Green Pro Taq HS Premix, final concentration is 0.2μmo1 / L Test 1, final concentration is 0.2μmo1 / L Test 2, and the balance is water. Set the reaction program: 95℃30sec; then enter the cycle stage: 95℃5sec, 60℃30sec, 40 cycles, and put it into the quantitative qPCR instrument for reaction.
[0143] (3) Data processing: Export the Ct value data obtained by the qPCR instrument, and prepare standard curves of the Ct value and the logarithm of the enzyme activity concentration of the control and test samples, respectively. The six concentration points are required to be linearly related and the correlation coefficient R 2 ≥0.99, Ct value must be within 13-30; the slope ratio of the standard curve of the test sample and the control sample is 1±0.03, take 5 dilution times of the test sample that conforms to the standard curve of the reference substance, calculate the logarithm of the enzyme activity of the test sample, calculate the enzyme activity at different dilution times after solving the logarithm, and then take the average value to obtain the enzyme activity of the corresponding test sample.
[0144] (4) Calculation of specific enzyme activity of MMLV reverse transcriptase: The enzyme activities of MMLV reverse transcriptase WT and MMLV reverse transcriptase mutants Mut1, Mut2, Mut3, Mut4, Mut5, and Mut6 calculated in (3) were divided by the concentration of the MMLV reverse transcriptase purified in Example 1 to calculate the specific enzyme activity of the MMLV reverse transcriptase.
[0145] The statistical results are as follows: Figure 2 As shown in the figure, it can be seen that the production of MMLV reverse transcriptase mutants Mut1, Mut2, Mut3, Mut4, Mut5, and Mut6 is greatly improved compared with the wild type.
[0146] Example 3 Detection of Tm Values of MMLV Reverse Transcriptase Mutants and Wild-type MMLV
[0147] In this example, the concentration of the MMLV reverse transcriptase mutant obtained in Example 1 was uniformly diluted to 500 ng / μL, and then the diluted mutant was subjected to differential scanning fluorescence to detect the Tm value of the MMLV reverse transcriptase mutant and the wild-type MMLV. The specific method is as follows:
[0148] The MMLV reverse transcriptase mutants Mut1, Mut2, Mut3, Mut4, Mut5, Mut6 and MMLV reverse transcriptase WT prepared in Example 1 were diluted to 500 ng / μL according to the concentration determined in Example 1, and the fluorescent dye SyproOrange was diluted to 20× using dimethyl sulfoxide (DMSO). After the diluted sample was mixed with Sypro Orange and DSF reaction buffer, it was placed in a real-time fluorescence quantitative PCR instrument, and the excitation and emission wavelengths were adjusted to the corresponding wavelengths of the fluorescent dye, and the temperature was increased to obtain a curve of fluorescence intensity changing with temperature, and the Tm value of the protein sample was calculated using software. The specific process is as follows:
[0149] (1) DSF reaction system: 20 μL DSF reaction system consists of 16 μL DSF reaction buffer with a final concentration of 1×, 2 μL protein sample with a concentration of 500 ng / μL, and 2 μL 20× fluorescent dye Sypro Orange.
[0150] (2) DSF reaction program: 4°C for 2 min; then enter the temperature rise program: the temperature change range is generally from 25°C to 99°C, 0.05°C / 10s, and the fluorescence intensity is measured once; select the X1M3 channel, place it in the real-time fluorescence quantitative PCR instrument, and start the temperature rise reaction.
[0151] (3) Data processing and analysis: The curve of fluorescence intensity changing with temperature is obtained, and the Tm value and related parameters of the protein sample are calculated on the software.
[0152] According to the Tm value obtained by software analysis, the curve is drawn. The results are as follows Figure 3 As shown in the figure, it can be seen that the Tm values of the MMLV reverse transcriptase mutants Mut1, Mut2, Mut3, Mut4, Mut5, and Mut6 prepared by the present invention are all improved, indicating that the thermal stability of the MMLV reverse transcriptase mutants is improved.
[0153] Example 4 RT-qPCR effect detection of thermostable MMLV reverse transcriptase mutants and wild-type MMLV reverse transcriptase at 60°C
[0154] In this example, the thermostable MMLV reverse transcriptase mutant obtained in Example 1 was diluted to 250 ng / μL, treated at 60°C for 15 min, and then subjected to RT-qPCR detection. The specific method is as follows:
[0155] The MMLV reverse transcriptase mutants Mut1, Mut2, Mut3, Mut4, Mut5, Mut6 and MMLV reverse transcriptase WT prepared in Example 1 were diluted to 250 ng / μL according to the concentration determined in Example 1, treated at 60°C for 15 min, and the treated and untreated MMLV reverse transcriptase mutants and WT were diluted to a final concentration of 0.5 ng / μL, 0.1 ng / μL, 0.02 ng / μL and 0.004 ng / μL; then reverse transcription was performed using 0.4 μg of MS2 RNA as a template; the obtained cDNA was amplified by qPCR to obtain the Ct value of the sample amplification. The specific process is as follows:
[0156] Test 1: 5'-TTCAGCGAACTTCTTGTAA-3' (SEQ ID NO: 15);
[0157] Test 2: 5'-CATCCGTAGCCTTATTGG-3' (SEQ ID NO: 16).
[0158] (1) Using 0.4 μg of MS2 RNA as a template, reverse transcription was performed using the diluted MMLV reverse transcriptase to obtain cDNA. The specific reverse transcription reaction system is as follows:
[0159] 20μL reverse transcription system: final concentration of 1×RTase Reaction Buffer Mix II, final concentration of 0.1μmo1 / L Test1, final concentration of 1U / μL RNase Inhibitor, 0.4μg MS2 RNA, 5μL diluted MMLV enzyme, add water to make up to 20μL.
[0160] The reverse transcription reaction program is 37℃, 30sec; 85℃, 5sec; 4℃, hold. Put it into the PCR instrument for reverse transcription reaction. After the reaction is completed, it can be placed at -20℃ for use.
[0161] (2) Quantitative qPCR reaction: The cDNA synthesized by reverse transcription in (1) was used as a template for qPCR reaction (N=2).
[0162] 25μL qPCR reaction system: final concentration is 1×SYBR Green Pro Taq HS Premix, final concentration is 0.2μmo1 / L Test 1, final concentration is 0.2μmo1 / L Test 2, and the balance is water. Set the reaction program: 95℃30sec; then enter the cycle stage: 95℃5sec, 60℃30sec, 40 cycles, and put it into the quantitative qPCR instrument for reaction.
[0163] Table 1
[0164]
[0165]
[0166] The experimental results obtained the Ct values of the samples after RT-qPCR without treatment and treatment at 60°C for 15 min, and the statistical results are shown in Table 1. The Ct value of the MMLV reverse transcriptase without treatment was subtracted from the Ct value of the MMLV reverse transcriptase treated at 60°C for 15 min at the corresponding concentration to obtain the △Ct value of a single sample; the △Ct value of the MMLV reverse transcriptase wild type was subtracted from the △Ct value of the MMLV reverse transcriptase mutant, and the curve was plotted. The results are shown in Table 1. Figure 4 As shown, it can be seen from the results that the Ct values of the MMLV reverse transcriptase mutants Mut1, Mut2, Mut3, Mut4, Mut5, and Mut6 prepared by the present invention were all advanced after being treated at 60°C for 15 minutes, and Mut3△Ct was the smallest, that is, after high temperature treatment, the RT-qPCR ability was the best.
[0167] Differential Scanning Fluorimetry (DSF) is a method for evaluating the thermal stability of proteins by slowly heating the sample on a fluorescent quantitative PCR instrument and detecting the amount of fluorescent dye combined with the structurally changed protein during the heating process. Through the DSF experiment, MMLV reverse transcriptases with high thermal stability can be screened out in high throughput.
[0168] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A thermostable MMLV reverse transcriptase mutant, It is characterized in that The amino acid sites are mutated based on the amino acid sequence of the wild-type MMLV reverse transcriptase as shown in SEQ ID NO: 1; the mutated sites include one or more of H126E, F199L, T246H, W388R, A404N and D422E.
2. The thermostable MMLV reverse transcriptase mutant according to claim 1, It is characterized in that The amino acid sequence of the thermostable MMLV reverse transcriptase mutant is shown in any one of SEQ ID NOs: 2-7.
3. A nucleic acid molecule, It is characterized in that The nucleic acid molecule encodes the thermostable MMLV reverse transcriptase mutant according to any one of claims 1-2.
4. A biological material associated with the nucleic acid molecule according to claim 3, It is characterized in that The biological material comprises at least one of a1) to a7): a1) an expression cassette comprising the nucleic acid molecule according to claim 3; a2) a vector comprising the nucleic acid molecule according to claim 3; a3) a vector comprising the expression cassette described in a1); a4) a transgenic cell line comprising the nucleic acid molecule according to claim 3; a5) a transgenic cell line comprising the expression cassette described in a1); a6) a transgenic cell line comprising the vector described in a2); a7) A transgenic cell line comprising the vector described in a3).
5. An enzyme preparation, It is characterized in that The invention comprises the high temperature resistant MMLV reverse transcriptase mutant according to any one of claims 1 to 2.
6. Use of at least one of the thermostable MMLV reverse transcriptase mutant according to any one of claims 1 to 2, the nucleic acid molecule according to claim 3, the biomaterial according to claim 4, and the enzyme preparation according to claim 5 in preparing a product; the product comprises at least one of a reagent, a detection plate, a test kit, and a detection chip.
7. The use according to claim 6, It is characterized in that The reagent, detection plate, detection chip or kit has at least one of the functions b1) to b3): b1) Detect RNA samples; b2) reverse transcription of RNA to synthesize cDNA; b3) Prepare RT-qPCR detection reagents.
8. The use according to claim 6, It is characterized in that The kit is selected from one of a reverse transcription reaction kit, a RT-PCR amplification kit, a RT-qPCR kit, a cDNA library construction kit, a cDNA end rapid amplification kit and an RNA sequencing kit.
9. A product, It is characterized in that The product comprises the thermostable MMLV reverse transcriptase mutant according to any one of claims 1 to 2; Preferably, the product comprises at least one of a reagent, a detection plate, a test kit, and a detection chip.
10. A method for preparing the thermostable MMLV reverse transcriptase mutant according to claim 1 or 2, It is characterized in that The following steps are involved: Obtained by expression of the transgenic cell line described in claim 4.
Citation Information
Patent Citations
Reverse transcriptase having improved thermostability
CN103348004A
Mutant reverse transcriptase with increased thermal stability as well as products, methods and uses involving the same
CN110709513A
Thermal stability reverse transcriptase mutant and application thereof
CN111647576A
Thermostable reverse transcriptase
CN112442493A
MMLV reverse transcriptase mutant and application thereof
CN116042569A
Cited By
MMLV reverse transcriptase mutant and application thereof
CN119955759A
MMLV reverse transcriptase mutant as well as preparation method, product and application thereof
CN121249621A
